ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of “Moderate Buy” from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $77.33.

Several analysts recently commented on ANIP shares. Truist Financial lifted their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Raymond James boosted their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. HC Wainwright reissued a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Finally, Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $58.40 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. ANI Pharmaceuticals has a one year low of $48.20 and a one year high of $70.81. The firm has a market capitalization of $1.23 billion, a P/E ratio of 49.91 and a beta of 0.71. The business has a fifty day moving average of $58.78 and a 200 day moving average of $61.60.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The company had revenue of $138.00 million during the quarter, compared to analyst estimates of $129.09 million. During the same quarter in the previous year, the company posted $1.06 earnings per share. ANI Pharmaceuticals’s revenue was up 18.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that ANI Pharmaceuticals will post 3.51 EPS for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Natixis Advisors LLC lifted its position in shares of ANI Pharmaceuticals by 56.2% in the third quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company’s stock valued at $1,085,000 after acquiring an additional 6,545 shares in the last quarter. Mizuho Markets Americas LLC purchased a new position in shares of ANI Pharmaceuticals in the third quarter valued at about $11,670,000. Victory Capital Management Inc. lifted its position in shares of ANI Pharmaceuticals by 153.6% in the third quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company’s stock worth $771,000 after buying an additional 7,825 shares in the last quarter. Summit Global Investments lifted its position in shares of ANI Pharmaceuticals by 154.2% in the third quarter. Summit Global Investments now owns 19,704 shares of the specialty pharmaceutical company’s stock worth $1,176,000 after buying an additional 11,952 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in shares of ANI Pharmaceuticals by 6.9% in the third quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock worth $5,367,000 after buying an additional 5,829 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.